The present invention relates to substituted dihydropyrido[3,4-b]pyrazinones as dual inhibitors of BET proteins, especially BRD4 proteins and polo-like kinases, especially Plk-1 proteins, of the general formula (I) in which A, X, R1, R2, R3, R4, R5, R6, R7 and n are each as defined in the description, to intermediates for preparation of the inventive compounds, to pharmaceutical compositions comprising the inventive compounds and to the prophylactic and therapeutic use thereof in hyperproliferative disorders, especially in neoplastic disorders. This invention further relates to the use of the inventive dihydropyrido[3,4-b]pyrazinones in viral infections, in neurodegenerative disorders, in inflammation disorders, in atherosclerotic disorders and in male fertility control.
